Garcia Rodriguez LA et al. - In the current study it was shown that low-dose aspirin therapy reduces the risk of stages B–D CRC.

Methods
The risk of CRC among new-users of low-dose aspirin (75–300 mg), including risk by stage at diagnosis, was studied.
Two cohorts (N = 170,336 each) free of cancer were identified and followed for 12 y: i) new-users of low-dose aspirin; and ii) non-users of low-dose aspirin.

Results
Current users of low-dose aspirin had a significantly reduced risk of CRC (RR = 0.66).
The RRs for current use of low-dose aspirin for Dukes stage A-D CRC, 0.94, 0.54, 0.71, and 0.60, respectively.
5 years after therapy the RR for Dukes stage A CRC was 0.53.